OptiNose (NASDAQ:OPTN) Stock Price Expected to Rise, HC Wainwright Analyst Says

OptiNose (NASDAQ:OPTN) had its price target lifted by investment analysts at HC Wainwright from $5.00 to $18.00 in a research note issued to investors on Friday, Marketbeat.com reports. The firm presently has a “buy” rating on the stock. HC Wainwright’s price objective would indicate a potential upside of 176.92% from the company’s current price. HC Wainwright also issued estimates for OptiNose’s FY2029 earnings at $1.41 EPS.

Separately, Piper Sandler decreased their target price on shares of OptiNose from $45.00 to $15.00 and set an “overweight” rating for the company in a research note on Wednesday, November 13th.

OptiNose Stock Down 3.0 %

OPTN opened at $6.50 on Friday. The stock has a market capitalization of $65.39 million, a price-to-earnings ratio of -23.21 and a beta of -0.15. The firm has a 50 day moving average price of $7.81 and a 200-day moving average price of $11.86. OptiNose has a twelve month low of $4.82 and a twelve month high of $31.50.

Hedge Funds Weigh In On OptiNose

Institutional investors have recently made changes to their positions in the business. Stonepine Capital Management LLC bought a new stake in OptiNose during the second quarter valued at approximately $2,444,000. Great Point Partners LLC grew its position in shares of OptiNose by 56.2% during the 2nd quarter. Great Point Partners LLC now owns 13,727,097 shares of the company’s stock valued at $14,276,000 after acquiring an additional 4,940,779 shares during the period. XTX Topco Ltd purchased a new stake in shares of OptiNose in the 2nd quarter worth $88,000. Squarepoint Ops LLC increased its stake in shares of OptiNose by 173.7% in the 2nd quarter. Squarepoint Ops LLC now owns 171,610 shares of the company’s stock worth $178,000 after purchasing an additional 108,903 shares in the last quarter. Finally, Massachusetts Financial Services Co. MA raised its holdings in OptiNose by 2.9% in the 2nd quarter. Massachusetts Financial Services Co. MA now owns 2,920,309 shares of the company’s stock worth $3,037,000 after purchasing an additional 81,233 shares during the period. Institutional investors own 85.60% of the company’s stock.

About OptiNose

OptiNose, Inc, a specialty pharmaceutical company, focuses on the development and commercialization of products for patients treated by ear, nose, throat, and allergy specialists in the United States. The company offers XHANCE, a therapeutic product utilizing its proprietary exhalation delivery system (EDS) that delivers a topically acting corticosteroid for the treatment of chronic rhinosinusitis with nasal polyps, as well as is in Phase IIIb clinical trial for treatment of chronic sinusitis; and Onzetra Xsail, a powder EDS device.